trial · primary record
Clarithromycin
Myeloma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 32 |
| Primary completion | 2024-11-11 |
| Primary endpoint | Maximum Tolerated Dose (MTD) (Phase I) |
| Registry ID | NCT02542657 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:23.901Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02542657
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.